HIV Drug Abacavir May Increase Risk for Cardiac Events

Health Canada Issues Safety Information

Health Canada in conjunction with GlaxoSmithKline warns that HIV-infected patients who are taking abacavir-containing products ZIAGEN, KIVEXA and TRIZIVIR may be at increased risk for myocardial infarction.

GlaxoSmithKline has provided Health Canada with recent findings published in the April 26, 2008, issue of The Lancet, regarding the ongoing prospective observational study, "The Data collection of Adverse effects of anti-HIV Drugs (D:A:D) Study", which was designed to quantify the incidence of myocardial infarction in HIV-infected patients receiving combination antiretroviral therapy. Analyses of data collected up to February 1, 2007, suggest that there is a potential increased risk of myocardial infarction in HIV-infected patients treated with abacavir-containing medicinal products.

Legal Help

If you or a loved one has suffered cardiac events from using these products, please click the link below to send your complaint to a lawyer to evaluate your claim at no cost or obligation.
Published on Jun-25-08